basic FUNCTION
| oxidoreductase activity |
|
regulating mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding |
|
regulating insulin-sensitivity of the Akt-mTOR pathway |
|
inhibiting cell growth, S6K1 phosphorylation and rheb-induced activation of the mTORC1 pathway |
|
potential target for the treatment of cancers, insulin resistance and hamartoma syndromes |
|
may be involved in neuroprotection |
|
potentially mediates apoptosis independently of its inhibitory effect on MTOR |
|
not involved in controlling MTOR, but rather is a downstream target of MTOR that is regulated in response only to specific stimuli, such as insulin) |
|
having ability to regulate the mammalian target of rapamycin complex 1 (MTOR) kinase activity, possessing a key regulatory role at the cross point of signal transduction pathways activated by growth factor receptors |
|
TSC2 and AKT1S1 are potent anti-apoptotic gatekeepers in early mammalian stem-cell differentiation, inhibiting embryoid bodies (EBs) degradation during early amniotic fluid stem (AFS) cell differentiation |
|
TSC2 and AKT1S1 are major anti-apoptotic regulators during early AFS cell differentiation due to their potential to control the rapamycin-insensitive functions of MTOR |
|
promotes the development of Ewing sarcoma family tumors |
|
is a potent and critical mediator of cardioprotection |
|
is a regulator of insulin sensitivity in human skeletal muscle cells (hSkMC) |
|
appears to reduce brain injury by converting cell signaling from AKT1 to MTOR |
|
connects microenvironmental stress signaling to exosome-mediated secretion |